Raw Report: Alphabet + GSK Fighting Diseases
GlaxoSmithKline and Alphabet’s (Google’s Parent Company) life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a new field of medicine known as bioelectronics.
Alphabet’s life-science arm, Verily (formerly known as Google Life Sciences), is to team up with pharma mega-company, GlaxoSmithKline, to establish a new bioelectronics research venture. The new company will be called Galvani Bioelectronics.
This is a very interesting investment for both companies, finally merging on big scale tech with life science. We will see more of these joint-ventures in the next coming years – since the Bioelectronics field is just about to breakthrough.
”Large-scale electrical devices have been used for years as heart pacemakers and, more recently, deep brain stimulation has been applied to treat Parkinson’s disease, severe depression and certain neurological movement disorders.
In future, however, the aim is to apply electrical interventions at the micro level, using tiny implants to coax insulin from cells to treat diabetes, for example, or correct muscle imbalances in lung diseases.”
GlaxoSmithKline and Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a new field of medicine known as bioelectronics. Verily Life Sciences-known as Google’s life sciences unit until last year-and Britain’s biggest drug maker will together contribute 540 million pounds ($715.12 million) over seven years to Galvani Bioelectronics, they said on Monday.